insights_auto
Why is AMRN down 2.49%?
Dive Deeperchevron_right
AMRN:NASDAQ
Amarin Corporation PLC
$11.38
arrow_downward
-2.49%(-0.29) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMRN...
Open
$11.67
High
$11.68
Low
$11.33
Mkt. cap
240.38M
Avg. vol.
78.82K
Volume
36.79K
52-wk high
$17.31
52-wk low
$11.25
EPS
-$0.92
Beta
0.81
Shares outstanding
21.07M
No. of employees
80
Open
$11.67
High
$11.68
Low
$11.33
Mkt. cap
240.38M
Avg. vol.
78.82K
Volume
36.79K
52-wk high
$17.31
52-wk low
$11.25
EPS
-$0.92
Beta
0.81
Shares outstanding
21.07M
No. of employees
80
News stories
From web sources and news partners
marketscreener.com
·
40 minutes ago
S&P 500, Nasdaq fall as Nvidia jitters drag down tech stocks
RealMoney Pro
·
7 minutes ago
Friday’s Charts – Stocks Notch Best Week Since August, Even as the 2-Year Jumps Most Since 2024
Traders Union
·
4 hours ago
S&P 500 gains $1.2 trillion in a week, Peter Tuchman notes
qz.com
·
3 hours ago
How much of the S&P 500 is Nvidia? Concentration explained
Profile
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
About Amarin Corporation PLC
CEO-
Employees80
FoundedMar 1, 1989
HeadquartersDublin, Leinster, Ireland
SectorHealth Care
IndustryBiotechnology
Websiteamarincorp.com